Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.33 and traded as high as $4.48. Sonoma Pharmaceuticals shares last traded at $3.83, with a volume of 1,273,066 shares changing hands.
Sonoma Pharmaceuticals Trading Down 9.7 %
The stock has a fifty day simple moving average of $1.07 and a two-hundred day simple moving average of $0.38. The company has a market cap of $65.75 million, a PE ratio of -4.74 and a beta of 1.37.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.00 earnings per share for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 65.66% and a negative net margin of 35.91%. The firm had revenue of $3.39 million for the quarter. As a group, equities research analysts anticipate that Sonoma Pharmaceuticals, Inc. will post -4 EPS for the current fiscal year.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.
See Also
- Five stocks we like better than Sonoma Pharmaceuticals
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 9/16 – 9/20
- Comparing and Trading High PE Ratio Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.